ArticleFrontiers in cell and developmental biology2026
Standardised dual-flow cytometry workflows for quantitative assessment of mitochondrial superoxide and mitochondrial mass in live cancer cells and primary multiple myeloma cells.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial metabolism plays a critical role in carcinogenesis and cancer progression. Quantitative assessment of mitochondrial function in live cells remains technically challenging because existing biochemical assays lack single-cell resolution, and microscopy-based approaches are limited in throughput and quantitative reproducibility. Here we describe a robust and reproducible standardised dual-flow cytometry protocol for simultaneous quantitative assessment of mitochondrial superoxide production and mitochondrial mass in live cancer cells and primary patient-derived multiple myeloma plasma cells using MitoSOX Green and MitoTracker Red. The protocol provides a step-by-step workflow comprising preparation of cultured cancer cells or isolation of primary CD138
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.